Two antibodies against IL-5 and one against IL-5Rα are now approved treatments for severe asthma associated with persistent eosinophilia, in addition to glucocorticoid therapy, reducing annualized exacerbation rates and moderately improving lung function (6). This evidence concerns the gene IL5 and asthma.